Document:

Blueprint

  Exhibit 4.1

 

Form of Warrant

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS
EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND
IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY
A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS
SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

 

THE CLASS N

 

COMMON STOCK PURCHASE WARRANT

 

 SANUWAVE HEALTH, INC.

 

	Warrant Shares:
_________	
Initial Exercise
Date: November 3,
2017

 

THIS
CLASS N COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that,
for value received, _______________ or its assigns (the
“Holder”) is entitled,
upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after November
3, 2017 (the “Initial Exercise Date”)
and on or prior to the close of business on March 17, 2019 (the
“Termination
Date”) but not thereafter, to subscribe for and
purchase from SANUWAVE Health, Inc., a Nevada corporation (the
“Company”), up to
__________ shares (as subject to adjustment hereunder, the
“Warrant
Shares”) of common stock, $0.001 par value, of the
Company (“Common
Stock”). The purchase price of one share of Common
Stock under this Warrant shall be equal to the Exercise Price, as
defined in Section 2(b).

 

Section
1.                                Definitions.
Capitalized terms used and not otherwise defined herein shall have
the meanings set forth in that certain Subscription Agreement (the
“Subscription
Agreement”), dated November 3, 2017, among the Company
and the purchasers signatory thereto.

 

 

 

 

Section
2.                                Exercise.

 

a) Exercise
of Warrant. Exercise of the purchase rights represented by
this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the
Termination Date by delivery to the Company (or such other office
or agency of the Company as it may designate by notice in writing
to the registered Holder at the address of the Holder appearing on
the books of the Company) of a duly executed facsimile copy of the
Notice of Exercise annexed hereto. Within three (3) business days
following the date of exercise as aforesaid, the Holder shall
deliver the aggregate Exercise Price for the shares specified in
the applicable Notice of Exercise by wire transfer or
cashier’s check drawn on a United States bank.
Notwithstanding anything herein to the contrary, the Holder shall
not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available
hereunder and the Warrant has been exercised in full, in which
case, the Holder shall surrender this Warrant to the Company for
cancellation within three (3) business days of the date the final
Notice of Exercise is delivered to the Company. Partial exercises
of this Warrant resulting in purchases of a portion of the total
number of Warrant Shares available hereunder shall have the effect
of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such
purchases. The Company shall deliver any objection to any Notice of
Exercise within one (1) business day of receipt of such notice.
The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason
of the provisions of this paragraph, following the purchase of a
portion of the Warrant Shares hereunder, the number of Warrant
Shares available for purchase hereunder at any given time may be
less than the amount stated on the face hereof.

 

b) Exercise Price. The exercise
price per share of the Common Stock under this Warrant shall be
$0.11, subject to adjustment
hereunder (the “Exercise
Price”).

 

c) Cashless Exercise. If at any
time there is no effective Registration Statement registering, or
no current prospectus available for, the resale of the Warrant
Shares by the Holder, then this Warrant may also be exercised, in
whole or in part, at such time by means of a “cashless
exercise” in which the Holder shall be entitled to receive a
number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:

 

 (A) = the
VWAP on the business day immediately preceding the date on which
Holder elects to exercise this Warrant by means of a
“cashless exercise,” as set forth in the applicable
Notice of Exercise;

 

(B) =
the Exercise Price of this Warrant, as adjusted hereunder;
and

 

(X) =
the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if
such exercise were by means of a cash exercise rather than a
cashless exercise.

 

Notwithstanding
anything herein to the contrary, on the Termination Date, this
Warrant shall be automatically exercised via cashless exercise
pursuant to this Section 2(c).

 

 

 

 

“VWAP” means, for any
date, the price determined by the first of the following clauses
that applies: (i) if the Common Stock is then listed or quoted on
an Exchange, the daily volume weighted average price of the Common
Stock for such date (or, if such date is not a Trading Day, the
nearest preceding Trading Day) on the primary Exchange on which the
Common Stock is then listed or quoted as reported by Bloomberg L.P.
(based on a Trading Day from 9:30 a.m. Eastern Time to 4:02 p.m.
Eastern Time); (ii) if the Common Stock is not then listed or
quoted on an Exchange and if prices for the Common Stock are then
reported in the “Pink” market published by OTC Markets
Group (or a similar organization or agency succeeding to its
functions of reporting prices), the most recent bid price per share
of the Common Stock so reported; or (iii) in all other cases, the
fair market value of a share of Common Stock as determined by a
nationally recognized-independent appraiser selected in good faith
by Holder and reasonably acceptable to the Company and whose fees
and expenses shall be borne by the Company (such value as
determined pursuant to this clause (iii), the “Fair Market
Value”).

 

The
“Exchange” means the New
York Stock Exchange, the NYSE MKT, the NASDAQ Global Select Market,
the NASDAQ Global Market, the NASDAQ Capital Market or OTC Bulletin
Board) or other national securities or over-the-counter exchange on
which the Common Stock is then listed.

 

d) Mechanics of
Exercise.

 

i.
Delivery of Certificates
Upon Exercise. Certificates for shares purchased hereunder
shall be transmitted by the Transfer Agent to the Holder by
crediting the account of the Holder’s prime broker with The
Depository Trust Company through its Deposit or Withdrawal at
Custodian system (“DWAC”) if the Company is
then a participant in such system and there is an effective
registration statement permitting the issuance of the Warrant
Shares to or resale of the Warrant Shares by the Holder, and
otherwise by physical delivery to the address specified by the
Holder in the Notice of Exercise by the date that is five (5)
business days after the latest of (A) the delivery to the Company
of the Notice of Exercise, (B) surrender of this Warrant (if
required) and (C) payment of the aggregate Exercise Price as set
forth above (such date, the “Warrant Share Delivery
Date”). The Warrant Shares shall be deemed to have
been issued, and the Holder or any other person so designated to be
named therein shall be deemed to have become a holder of record of
such shares for all purposes, as of the date the Warrant has been
exercised, with payment to the Company of the Exercise Price and
all taxes required to be paid by the Holder, if any, pursuant to
Section 2(c)(v) prior to the issuance of such shares, having been
paid.

 

ii.
Delivery of New Warrants
Upon Exercise. If this Warrant shall have been exercised in
part, the Company shall, at the request of a Holder and upon
surrender of this Warrant, at the time of delivery of the
certificate or certificates representing Warrant Shares, deliver to
the Holder a new Warrant evidencing the rights of the Holder to
purchase the unpurchased Warrant Shares called for by this Warrant,
which new Warrant shall in all other respects be identical with
this Warrant.

 

 

 

 

iii.
Rescission Rights.
If the Company fails to cause the Transfer Agent to transmit to the
Holder a certificate or the certificates representing the Warrant
Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery
Date, then the Holder will have the right to rescind such
exercise.

 

      iv.
Compensation for Buy-In on
Failure to Timely Deliver Warrant Shares Upon Exercise. In
addition to any other rights available to the Holder, if the
Company fails to cause the Transfer Agent to transmit to the Holder
the Warrant Shares pursuant to an exercise on or before the Warrant
Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or
otherwise) or the Holder’s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a
sale by the Holder of the Warrant Shares which the Holder
anticipated receiving upon such exercise (a “Buy-In”), then the
Company shall (A) pay in cash to the Holder the amount, if any, by
which (x) the Holder’s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so
purchased exceeds (y) the amount obtained by multiplying (1) the
number of Warrant Shares that the Company was required to deliver
to the Holder in connection with the exercise at issue times (2)
the price at which the sell order giving rise to such purchase
obligation was executed, and (B) at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number
of Warrant Shares for which such exercise was not honored (in which
case such exercise shall be deemed rescinded) or deliver to the
Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and
delivery obligations hereunder. For example, if the Holder
purchases Common Stock having a total purchase price of $11,000 to
cover a Buy-In with respect to an attempted exercise of shares of
Common Stock with an aggregate sale price giving rise to such
purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder
$1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the
Buy-In and, upon request of the Company, evidence of the amount of
such loss. Nothing herein shall limit a Holder’s right to
pursue any other remedies available to it hereunder, at law or in
equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the
Company’s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms
hereof.

 

v.
No Fractional Shares or
Scrip. No fractional shares or scrip representing fractional
shares shall be issued upon the exercise of this Warrant. As to any
fraction of a share which the Holder would otherwise be entitled to
purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in
an amount equal to such fraction multiplied by the Exercise Price
or round up to the next whole share.

 

 

 

 

vi.
Charges, Taxes and
Expenses. Issuance of certificates for Warrant Shares shall
be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such
certificate, all of which taxes and expenses shall be paid by the
Company, and such certificates shall be issued in the name of the
Holder or in such name or names as may be directed by the Holder;
provided,
however, that in
the event certificates for Warrant Shares are to be issued in a
name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment
Form attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum
sufficient to reimburse it for any transfer tax incidental
thereto.

 

vii.
Closing of Books.
The Company will not close its stockholder books or records in any
manner which prevents the timely exercise of this Warrant, pursuant
to the terms hereof.

 

e) Holder’s Exercise
Limitations. The Company shall not effect any exercise of
this Warrant, and a Holder shall not have the right to exercise any
portion of this Warrant, pursuant to Section 2 or otherwise, to the
extent that after giving effect to such issuance after exercise as
set forth on the applicable Notice of Exercise, the Holder
(together with the Holder’s Affiliates, and any other Persons
acting as a group together with the Holder or any of the
Holder’s Affiliates), would beneficially own in excess of the
Beneficial Ownership Limitation (as defined below).  For
purposes of the foregoing sentence, the number of shares of Common
Stock beneficially owned by the Holder and its Affiliates shall
include the number of shares of Common Stock issuable upon exercise
of this Warrant with respect to which such determination is being
made, but shall exclude the number of shares of Common Stock which
would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of
its Affiliates and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company
(including, without limitation, any other securities convertible
into Common Stock) subject to a limitation on conversion or
exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates.  Except as set
forth in the preceding sentence, for purposes of this Section 2(e),
beneficial ownership shall be calculated in accordance with Section
13(d) of the Securities Exchange Act of 1934, as amended (the
“Exchange
Act”) and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is
not representing to the Holder that such calculation is in
compliance with Section 13(d) of the Exchange Act and the Holder is
solely responsible for any schedules required to be filed in
accordance therewith. To the extent that the limitation contained
in this Section 2(e) applies, the determination of whether this
Warrant is exercisable (in relation to other securities owned by
the Holder together with any Affiliates) and of which portion of
this Warrant is exercisable shall be in the sole discretion of the
Holder, and the submission of a Notice of Exercise shall be deemed
to be the Holder’s determination of whether this Warrant is
exercisable (in relation to other securities owned by the Holder
together with any Affiliates) and of which portion of this Warrant
is exercisable, in each case subject to the Beneficial Ownership
Limitation, and the Company shall have no obligation to verify or
confirm the accuracy of such determination. In addition, a
determination as to any group status as contemplated above shall be
determined in accordance with Section 13(d) of the Exchange Act and
the rules and regulations promulgated thereunder. For purposes of
this Section 2(e), in determining the number of outstanding shares
of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company’s most
recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Transfer
Agent setting forth the number of shares of Common Stock
outstanding.  Upon the written or oral request of a Holder,
the Company shall within two (2) business days confirm orally and
in writing to the Holder the number of shares of Common Stock
outstanding pursuant to prior sentence.  In any case, the
number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of
the Company, including this Warrant, by the Holder or its
Affiliates since the date as of which such number of outstanding
shares of Common Stock was reported. The “Beneficial Ownership
Limitation” shall be 4.99% of the number of shares of
the Common Stock outstanding immediately after giving effect to the
issuance of shares of Common Stock issuable upon exercise of all or
any portion of this Warrant. The Holder, upon not less than 61
days’ prior notice to the Company, may increase or decrease
the Beneficial Ownership Limitation provisions of this Section
2(e), provided that the Beneficial Ownership Limitation in no event
exceeds 9.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of
shares of Common Stock upon exercise of this Warrant held by the
Holder and the provisions of this Section 2(e) shall continue to
apply. Any such increase or decrease will not be effective until
the 61st
day after such notice is delivered to the Company. The provisions
of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section
2(e) to correct this paragraph (or any portion hereof) which may be
defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation.
The limitations contained in this paragraph shall apply to a
successor holder of this Warrant.

 

 

 

 

Section 3. Certain
Adjustments.

 

a) Stock Dividends and Splits. If
the Company, at any time while this Warrant is outstanding: (i)
pays a stock dividend or otherwise makes a distribution or
distributions on shares of its Common Stock or any other equity or
equity equivalent securities payable in shares of Common Stock
(which, for avoidance of doubt, shall not include any shares of
Common Stock issued by the Company upon exercise of this Warrant),
(ii) subdivides outstanding shares of Common Stock into a larger
number of shares, (iii) combines (including by way of reverse stock
split) outstanding shares of Common Stock into a smaller number of
shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case
the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding
treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of
Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be
proportionately adjusted such that the aggregate Exercise Price of
this Warrant shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the
record date for the determination of stockholders entitled to
receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision,
combination or re-classification.

 

b) Combination: Liquidation. While
this Warrant is outstanding,

 

(i)

In the event of a
Combination (as defined below), each Holder shall have the right to
receive upon exercise of the Warrant the kind and amount of shares
of capital stock or other securities or property which such Holder
would have been entitled to receive upon or as a result of such
Combination had such Warrant been exercised immediately prior to
such event (subject to further adjustment in accordance with the
terms hereof). Unless paragraph (ii) is applicable to a
Combination, the Company shall provide that the surviving or
acquiring Person (the “Successor Company”) in
such Combination will assume by written instrument the obligations
under this Section 3 and the
obligations to deliver to the Holder such shares of stock,
securities or assets as, in accordance with the foregoing
provisions, the Holder may be entitled to acquire.
“Combination” means an
event in which the Company consolidates with, mergers with or into,
or sells all or substantially all of its assets to another Person,
where “Person” means any
individual, corporation, partnership, joint venture, limited
liability company, association, joint-stock company, trust,
unincorporated organization, government or any agency or political
subdivision thereof or any other entity;

 

(ii)

In the event of (x)
a Combination where consideration to the holders of Common Stock in
exchange for their shares is payable solely in cash or (y) the
dissolution, liquidation or winding-up of the Company, the Holders
shall be entitled to receive, upon surrender of their Warrant,
distributions on an equal basis with the holders of Common Stock or
other securities issuable upon exercise of the Warrant, as if the
Warrant had been exercised immediately prior to such event, less
the Exercise Price. In case of any Combination described in this
Section 3, the
surviving or acquiring Person and, in the event of any dissolution,
liquidation or winding-up of the Company, the Company, shall
deposit promptly with an agent or trustee for the benefit of the
Holders of the funds, if any, necessary to pay to the Holders the
amounts to which they are entitled as described above. After such
funds and the surrendered Warrant are received, the Company is
required to deliver a check in such amount as is appropriate (or,
in the case or consideration other than cash, such other
consideration as is appropriate) to such Person or Persons as it
may be directed in writing by the Holders surrendering such
Warrant.

 

 

 

 

c) Calculations. All calculations
under this Section 3 shall be made to the nearest cent or the
nearest 1/100th of a share, as the case may be. For purposes of
this Section 3, the number of shares of Common Stock deemed to be
issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if
any) issued and outstanding.

 

d) Notice to Holder.

 

i. Adjustment to Exercise Price.
Whenever the Exercise Price is adjusted pursuant to any provision
of this Section 3, the Company shall promptly mail to the Holder a
notice setting forth the Exercise Price after such adjustment and
any resulting adjustment to the number of Warrant Shares and
setting forth a brief statement of the facts requiring such
adjustment.

 

ii. Notice to Allow Exercise by
Holder. If (A) the Company shall declare a dividend (or any
other distribution in whatever form) on the Common Stock, (B) the
Company shall declare a special nonrecurring cash dividend on or a
redemption of the Common Stock, (C) the Company shall authorize the
granting to all holders of the Common Stock rights or warrants to
subscribe for or purchase any shares of capital stock of any class
or of any rights, (D) the approval of any stockholders of the
Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the
Company is a party, any sale or transfer of all or substantially
all of the assets of the Company, or any compulsory share exchange
whereby the Common Stock is converted into other securities, cash
or property, or (E) the Company shall authorize the voluntary or
involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be
mailed to the Holder at its last address as it shall appear upon
the Warrant Register of the Company, at least 20 calendar days
prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be
taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are
to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected
to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be
entitled to exchange their shares of the Common Stock for
securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share
exchange; provided that the failure to mail such notice or any
defect therein or in the mailing thereof shall not affect the
validity of the corporate action required to be specified in such
notice. To the extent that any notice provided hereunder
constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall
simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to
exercise this Warrant during the period commencing on the date of
such notice to the effective date of the event triggering such
notice except as may otherwise be expressly set forth
herein.

 

 

 

 

Section 4. Transfer of
Warrant.

 

a) Transferability. This Warrant
and all rights hereunder (including, without limitation, any
registration rights) are transferable, in whole or in part, upon
surrender of this Warrant at the principal office of the Company or
its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by
the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such
surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee
or assignees, as applicable, and in the denomination or
denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this
Warrant not so assigned, and this Warrant shall promptly be
cancelled. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of
Warrant Shares without having a new Warrant issued.

 

b) New Warrants. This Warrant may
be divided or combined with other Warrants upon presentation hereof
at the aforesaid office of the Company, together with a written
notice specifying the names and denominations in which new Warrants
are to be issued, signed by the Holder or its agent or attorney.
Subject to compliance with Section 4(a), as to any transfer which
may be involved in such division or combination, the Company shall
execute and deliver a new Warrant or Warrants in exchange for the
Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be
dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant
Shares issuable pursuant thereto.

 

c) Warrant Register. The Company
shall register this Warrant, upon records to be maintained by the
Company for that purpose (the “Warrant Register”), in
the name of the record Holder hereof from time to time. The Company
may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent
actual notice to the contrary.

 

d) Transfer
Restrictions. If, at the
time of the surrender of this Warrant
in connection with any transfer of this Warrant, the transfer of
this Warrant shall not be either (i) registered pursuant to an
effective registration
 statement under the
Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for
resale without volume or manner-of-sale restrictions or current
public information requirements pursuant to Rule 144, the Company
may require, as a condition of allowing such transfer, that the
Holder or transferee of this Warrant, as the case may be, comply
with the provisions of Section 2 of the Subscription
Agreement.

 

e) Representation by the Holder.
The Holder, by the acceptance hereof, represents and warrants that
it is acquiring this Warrant and, upon any exercise hereof, will
acquire the Warrant Shares issuable upon such exercise, for its own
account and not with a view to or for distributing or reselling
such Warrant Shares or any part thereof in violation of the
Securities Act or any applicable state securities law, except
pursuant to sales registered or exempted under the Securities
Act.

 

 

 

 

Section
5.                                Miscellaneous.

 

a) No Rights as Stockholder Until
Exercise. This Warrant does not entitle the Holder to any
voting rights, dividends or other rights as a stockholder of the
Company prior to the exercise hereof as set forth in Section
2(d)(i).

 

b) Loss, Theft, Destruction or Mutilation
of Warrant. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss,
theft, destruction or mutilation of this Warrant or any stock
certificate relating to the Warrant Shares, and in case of loss,
theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Warrant, shall not
include the posting of any bond), and upon surrender and
cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock
certificate of like tenor and dated as of such cancellation, in
lieu of such Warrant or stock certificate.

 

c) Saturdays, Sundays, Holidays,
etc. If the last or appointed day for the taking of any
action or the expiration of any right required or granted herein
shall not be a business day, then, such action may be taken or such
right may be exercised on the next succeeding business
day.

 

d) Authorized Shares. The Company
covenants that, during the period the Warrant is outstanding, it
will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the
Warrant Shares upon the exercise of any purchase rights under this
Warrant. The Company further covenants that its issuance of this
Warrant shall constitute full authority to its officers who are
charged with the duty of executing stock certificates to execute
and issue the necessary certificates for the Warrant Shares upon
the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure
that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any
requirements of the Exchange upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be
issued upon the exercise of the purchase rights represented by this
Warrant will, upon exercise of the purchase rights represented by
this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and
nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in
respect of any transfer occurring contemporaneously with such
issue).

 

Except
and to the extent as waived or consented to by the Holder, the
Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any
reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any
of the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking of
all such actions as may be necessary or appropriate to protect the
rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will
(i) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to
such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable Warrant Shares upon
the exercise of this Warrant and (iii) use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations
under this Warrant.

 

 

 

 

Before
taking any action which would result in an adjustment in the number
of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or
exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction
thereof.

 

e) Jurisdiction. All questions
concerning the construction, validity, enforcement and
interpretation of this Warrant shall be determined in accordance
with the provisions of the Subscription Agreement.

 

f) Restrictions. The Holder
acknowledges that the Warrant Shares acquired upon the exercise of
this Warrant, if not registered, will have restrictions upon resale
imposed by state and federal securities laws.

 

g) Nonwaiver and Expenses. No
course of dealing or any delay or failure to exercise any right
hereunder on the part of Holder shall operate as a waiver of such
right or otherwise prejudice the Holder’s rights, powers or
remedies. Without limiting any other provision of this Warrant or
the Subscription Agreement, if the Company willfully and knowingly
fails to comply with any provision of this Warrant, which results
in any material damages to the Holder, the Company shall pay to the
Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys’
fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in
otherwise enforcing any of its rights, powers or remedies
hereunder.

 

h) Notices. Any notice, request or
other document required or permitted to be given or delivered to
the Holder by the Company shall be delivered in accordance with the
notice provisions of the Subscription Agreement.

 

i) Limitation of Liability. No
provision hereof, in the absence of any affirmative action by the
Holder to exercise this Warrant to purchase Warrant Shares, and no
enumeration herein of the rights or privileges of the Holder, shall
give rise to any liability of the Holder for the purchase price of
any Common Stock or as a stockholder of the Company, whether such
liability is asserted by the Company or by creditors of the
Company.

 

j) Remedies. The Holder, in
addition to being entitled to exercise all rights granted by law,
including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees
that monetary damages would not be adequate compensation for any
loss incurred by reason of a breach by it of the provisions of this
Warrant and hereby agrees to waive and not to assert the defense in
any action for specific performance that a remedy at law would be
adequate.

 

k) Successors and Assigns. Subject
to applicable securities laws, this Warrant and the rights and
obligations evidenced hereby shall inure to the benefit of and be
binding upon the successors and permitted assigns of the Company
and the successors and permitted assigns of Holder. The provisions
of this Warrant are intended to be for the benefit of any Holder
from time to time of this Warrant and shall be enforceable by the
Holder or holder of Warrant Shares.

 

 

 

 

l) Amendment. This Warrant may be
modified or amended or the provisions hereof waived with the
written consent of the Company and the
Holder.

 

m) Severability. Wherever
possible, each provision of this Warrant shall be interpreted in
such manner as to be effective and valid under applicable law, but
if any provision of this Warrant shall be prohibited by or invalid
under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the
remainder of such provisions or the remaining provisions of this
Warrant.

 

n) Headings. The headings used in
this Warrant are for the convenience of reference only and shall
not, for any purpose, be deemed a part of this
Warrant.

 

 

********************

 

(Signature Page Follows)

 

 

 

 

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed
by its officer thereunto duly authorized as of the date first above
indicated.

 

 

	

SANUWAVE HEALTH, INC.

 

 

	

By:__________________________________________

     Name:
Lisa E. Sundstrom

     Title:
Chief Financial Officer

 

 

 

 

 

 

 

NOTICE OF EXERCISE

 

TO:            

SANUWAVE HEALTH,
INC.

 

(1) The undersigned
hereby elects to purchase ________________ Warrant Shares of the
Company pursuant to the terms of the attached Warrant, and tenders
herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.

 

(2) Please issue a
certificate or certificates representing said Warrant Shares in the
name of the undersigned or in such other name as is specified
below*:

 

_______________________________

 

 

*If a
name other than the Holder is specified, please complete the Share
Assignment Form.

 

The
Warrant Shares shall be delivered to the following DWAC Account
Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

 

 

_________________________________________________

Signature of Holder / Authorized Signatory

 

_________________________________________________

Name of
Holder

 

_________________________________________________

Name of
Authorized Signatory

 

_________________________________________________

Title
of Authorized Signatory

 

_________________________________________________

Date

 

 

 

 

SHARE ASSIGNMENT FORM

 [To
assign the shares being issued pursuant to the foregoing warrant,
execute this form and supply required information. Do not use this
form to assign or exercise the warrant.]

 

FOR
VALUE RECEIVED, [all of / _______________________________________]
shares of the foregoing Warrant and all rights evidenced thereby
are hereby assigned to

_______________________________________________
whose address is:

_______________________________________________________________.

 

Dated:
______________, _______

	

 

 

In
connection with any transfer of the Warrant, the undersigned
confirms that it has not utilized any general solicitation or
general advertising in connection with the transfer and is making
the transfer pursuant to one of the following:

[Check
All That Apply]

(1)
___                      to
the Company; or

(2)
___                      to
an “accredited investor” (as defined in Rule 501(a)
under the Securities Act of 1933, as amended (the “Securities
Act”)); or

(3)
___                      pursuant
to the exemption from registration provided by Rule 144 under the
Securities Act or pursuant to another exemption available under the
Securities Act; or

(4)
___                      pursuant
to an effective registration statement under the Securities
Act.

If the
box is checked below, the undersigned confirms and represents to
the Company that the Warrant is not being transferred to an
“affiliate” of the Company as defined in Rule 144 of
the Securities Act.

 

☐ The
transferee is not an “affiliate” of the Company as
defined in Rule 144 of the Securities Act.

 

Holder’s
Signature:    

_____________________________

 

Holder’s
Address:       

_____________________________

      

 

      

_____________________________

 

Signature
Guaranteed:
___________________________________________

 

NOTE:
The signature to this Share Assignment Form must correspond with
the name as it appears on the face of the Warrant, without
alteration or enlargement or any change whatsoever, and must be
guaranteed by a bank or trust company. Officers of corporations and
those acting in a fiduciary or other representative capacity should
file proper evidence of authority to assign the
foregoing.

 

 

 

 

WARRANT ASSIGNMENT FORM

[To be
completed and signed only upon transfer of Warrant]

 

[FOR
VALUE RECEIVED,] the undersigned hereby [sells], assigns and
transfers unto ________________________________ the right
represented by the within Warrant to purchase ____________ Warrant
Shares to which the within Warrant relates and appoints
________________ attorney to transfer said right on the books of
SANUWAVE Health, Inc. (the “Company”) with full power
of substitution in the premises.

 

	

In
connection with any transfer of the Warrant, the undersigned
confirms that it has not utilized any general solicitation or
general advertising in connection with the transfer and is making
the transfer pursuant to one of the following:

[Check
All That Apply]

(1)
___                      to
the Company; or

(2)
___                      to
an “accredited investor” (as defined in Rule 501(a)
under the Securities Act of 1933, as amended (the “Securities
Act”)); or

(3)
___                      pursuant
to the exemption from registration provided by Rule 144 under the
Securities Act or pursuant to another exemption available under the
Securities Act; or

(4)
___                      pursuant
to an effective registration statement under the Securities
Act.

If the
box is checked below, the undersigned confirms and represents to
the Company that the Warrant is not being transferred to an
“affiliate” of the Company as defined in Rule 144 of
the Securities Act.

 

☐ The
transferee is not an “affiliate” of the Company as
defined in Rule 144 of the Securities Act.

	

 

Dated:                           ,           

	
 

	
 

	
 

	
 

	

              
______________________________

	
 

	
 

	
 

	
              
______________________________

	
 

	

Address
of Transferee

	
 

	
 

	
 

	

              
______________________________

	
 

	
 

	
 

	

              
______________________________

	
 

	
 

	

In the
presence of:Blueprint

  Exhibit 10.1

 

SANUWAVE HEALTH, INC.

 

10% CONVERTIBLE PROMISSORY NOTE

 

	
$___,000.00

	

November
3, 2017

  Suwanee,
Georgia 

  

FOR VALUE RECEIVED, the undersigned,
SANUWAVE HEALTH, INC. (the
“Company”),
promises to pay to the order of ________, or his/her/its registered
assigns (the “Holder”),
the principal sum of ______ Dollars ($____,000.00), with interest
thereon from time to time as provided herein.

 

1.           Maturity
Date; Repayment; Interest. The principal under this Note
(“Principal”), together with interest calculated at the
rate of ten percent (10%) per annum on the Principal from the date
of issuance of the Note until six (6) months after the date of
issuance of the Note (the “Interest”), shall be due
and payable on the earlier of (i) six (6) months after the date of
issuance of the Note (the “Maturity
Date”) or (ii) the Prepayment Date (as defined below),
provided the Note is not converted in accordance with Section 3 below. The Principal
and the Interest shall not be payable or callable under the Note
until the earlier of (a) the Maturity Date or (b) the Prepayment
Date. No principal or interest shall be payable or callable under
this Note until the earlier of (a) the Maturity Date or (b) the
Prepayment Date.

 

2.           Prepayment.
 The Company may prepay
the Principal and Interest in cash, in whole but not in part, prior
to the Maturity Date or the conversion of the Note (the
“Prepayment
Date”) with twenty (20) days’ written notice to
the Holder.

 

3.            

Conversion.

 

 (a)           Immediately
upon issuance until the repayment in full of this Note, in the sole
and absolute discretion of the Holder, the Principal and Interest,
in whole or in part, shall be convertible at any time into shares
of common stock, $0.001 par value, of the Company
(“Common
Stock”), the number of such shares to be equal to the
amount obtained by dividing (i) the amount of the unpaid principal
and interest on this Note to be converted, by (ii) $0.11, by
submitting to the Company a notice of conversion, a form of which
is attached hereto as Annex A (by facsimile or other reasonable
means of communications, to the attention of the Chief Financial
Officer).

 

(b)           In
the event of any conversion as provided above, the Company shall
not issue fractional securities but shall pay the dollar equivalent
of any fractional securities that would otherwise be
issuable.

 

(c)           The
Company shall not be obligated to issue certificates evidencing the
securities issuable upon such conversion unless the Note is either
delivered to the Company or the Holder notifies the Company that
such Note has been lost, stolen or destroyed and executes an
agreement satisfactory to the Company to indemnify the Company from
any loss incurred by it in connection with such Note. The Company
shall, as soon as practicable after such delivery, or such
agreement and indemnification, issue and deliver at such office to
such holder of the Note, a certificate or certificates for the
securities to which the Holder shall be entitled as the result of a
conversion, as mutually agreed to between the Company and the
Holder. The person or persons entitled to receive securities
issuable upon such conversion shall be treated for all purposes as
the record holder or holders of such securities on such
date.

 

 

1

 

 

(d)           In
the event that any principal of or interest on this Note remains
unpaid at any time after payment thereof is due hereunder, the
Holder shall retain all rights hereunder until such time as amounts
due, including additional accrued interest, have been paid in full.
Subject to the foregoing, upon (i) either (x) payment in full by
the Company to the Holder of all principal, interest and any other
amounts due pursuant to the terms hereof or (y) conversion of this
Note in full pursuant to the terms hereof, and
(ii) fulfillment by the Company of all its other material
obligations hereunder, this Note shall terminate.

 

4.           Defaults
and Remedies.

 

(a)           In
the event the principal is not paid in full within three (3)
business days of the due date stipulated above, or any other
default occurs, then, from and after such date and until payment in
full of the amount due hereunder, interest shall accrue on the
outstanding principal balance of this Note at the simple rate equal
to eighteen percent (18%) per annum. Time is of the essence of this
Note.

 

(b)           Presentment
for payment, demand, protest and notice of demand, dishonor,
protest and non-payment and all other notices are hereby waived by
the Company. No acceptance of a partial installment, late payment
or indulgences granted from time to time shall be construed
(i) as a novation of this Note or as a reinstatement of the
indebtedness evidenced hereby or as a waiver of the right of the
Holder thereafter to insist upon strict compliance with the terms
of this Note, or (ii) to prevent the exercise of any right
granted hereunder or by the laws of the State of Georgia; and the
Company hereby expressly waives the benefit of any statute or rule
of law or equity now provided, or which may hereafter be provided,
which would produce a result contrary to or in conflict with the
foregoing. No extension of the time for the payment of this Note or
any installment due hereunder, made by agreement with any person
now or hereafter liable for the payment of this Note, shall operate
to release, discharge, modify, change or affect the original
liability of the Company under this Note, either in whole or in
part, unless the Holder agrees otherwise in writing.

 

(c)           If
for any circumstances whatsoever, fulfillment of any provision of
this Note or of any other instrument evidencing or securing the
indebtedness evidenced hereby, at the time performance of such
provision shall be due, shall involve transcending the limit of
validity presently prescribed by any applicable usury statute or
any other applicable law, with regard to obligations of like
character and amount, then, the obligation to be fulfilled shall be
reduced to the limit of such validity, so that in no event shall
any action be possible under this Note or under any other
instrument evidencing or securing the indebtedness evidenced
hereby, that is in excess of the current limit of such validity,
but such obligation shall be fulfilled to the limit of such
validity.

 

5.           Remedies
Cumulative. No remedy herein conferred upon the Holder is
intended to be exclusive of any other remedy and each and every
such remedy shall be cumulative and shall be in addition to every
other remedy given hereunder or now or hereafter existing at law or
in equity or by statute or otherwise. To the extent permitted by
applicable law, the Company and the Holder waive presentment for
payment, demand, protest and notice of dishonor.

 

6.           Governing
Law. This Note shall be governed by and construed in
accordance with the laws of the State of Georgia regardless of
conflicts of law principles.

 

7.           Assignment.
The Company shall not assign its rights or obligations under this
Note to any third party. Any assignment in breach of the foregoing
shall be void and of no force or effect. The Holder may assign his,
her, or its rights under this Note as allowed by law.

 

 

2

 

 

8.           Amendment/Waiver.
No term of this Note may be amended and the observance of any term
of this Note may not be waived except with the written consent of
the Company and Holder hereof.

 

 

IN WITNESS WHEREOF, this Note has been
executed by the Company by its duly authorized officer as of the
day and year first written above.

 

 

 

SANUWAVE
Health, Inc.

 

 

 

By:                                                                         

 

Name:
___________________________________

 

Title:
____________________________________

 

 

 

 

 

 

3

 

Annex A

 

NOTICE OF CONVERSION OF

CONVERTIBLE PROMISSORY NOTE

 

 (To be Executed by the Registered Holder in Order to Convert
the Note)

 

 

 

 

 

FROM:
     
                 
                 
                 
                 
                 
               
(“Holder”)

 

 

 

DATE:                                                                                           
(the “Conversion Date”)

 

 

RE: 

Conversion of the
Convertible Promissory Note (the “Note”) of
SANUWAVE HEALTH, INC. (the
“Company”) into shares of Common Stock (defined
below)

 

TO: 

SANUWAVE HEALTH,
INC.

CHIEF
FINANCIAL OFFICER

3360
Martin Farm Road, Suite 100

Suwanee, Georgia
30024

Telephone: (678)
578-0117

Facsimile: (678)
569-0881

Email:
lisa.sundstrom@sanuwave.com

 

The
captioned Holder hereby gives notice to the Company, pursuant to
Section 3(a) of the Note of SANUWAVE HEALTH, INC., that the Holder elects to convert
$________________ of the unpaid principal amount of, and unpaid
interest on, the Note into fully paid and non-assessable shares of
common stock, $0.001 par value, of the Company (“Common
Stock”) as of the Conversion Date specified
above.

 

 

 

___________________________________

 

(Print
name of Holder)

 

By:
_______________________________

 

(Signature
of Authorized Person)

 

___________________________________

 

(Printed
Name and Title)

 

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]